-
公开(公告)号：WO2023090409A1
公开(公告)日：2023-05-25
申请号：PCT/JP2022/042785
申请日：2022-11-18
Applicant: ＪＣＲファーマ株式会社
IPC: A61K39/395 , A61K39/44 , A61K45/00 , A61K48/00 , A61P3/00 , A61P3/08 , A61P9/10 , A61P21/00 , A61P21/04 , A61P35/00 , A61P43/00 , C07K16/18 , C07K16/28 , C07K16/46 , C07K19/00 , C12N5/10 , A61K47/62 , A61K47/64 , A61K47/65 , A61K47/68 , C12N1/15 , C12N1/19 , C12N1/21 , C12N15/12 , C12N15/13 , C12N15/52 , C12N15/62 , C12N15/63 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/21 , A61K38/38 , A61K38/43 , A61K38/46 , A61K38/48 , C12P21/08 , C07K14/475 , C07K14/48 , C07K14/485 , C07K14/50 , C07K14/505 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/56 , C07K14/565 , C07K14/57 , C07K14/705 , A61K31/7088 , A61P25/00 , A61P25/02 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , C12N9/14
Abstract: 本発明は，その一実施形態において，中枢神経系（CNS）において機能させるべき化合物（蛋白質，核酸，低分子化合物等）をして血液脳関門を通過させるために，それらの化合物の何れかと結合させて用いることのできる，ヒトトランスフェリン受容体に親和性を有するペプチド，及びその用途に関する。当該ペプチドは，例えば，配列番号３～７及びは５５で示されるアミノ酸配列からなる群より選択されるアミノ酸配列を含むもの，又はその変異体である。
-
2.发明申请
公开(公告)号：WO2023086900A1
公开(公告)日：2023-05-19
申请号：PCT/US2022/079659
申请日：2022-11-10
Inventor： PORRAS PANIAGUA, Matias , GILL, Saar , BENNETT, Frederick
Abstract: The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) specific for amyloid beta (Αβ) and/or Tau. In certain embodiments, the CARs do not comprise an intracellular domain. Methods of treatment are also disclosed herein.
-
公开(公告)号：WO2023083327A1
公开(公告)日：2023-05-19
申请号：PCT/CN2022/131502
申请日：2022-11-11
Applicant: 上海生物制品研究所有限责任公司
IPC: C07K16/28 , C07K19/00 , C12N5/10 , C12N15/13 , C12N15/62 , C12N15/63 , A61K39/395 , A61P35/00 , G01N33/53
Abstract: 本发明提供了抗CLDN18.2单克隆抗体及其制剂。具体地，本发明提供了一种新的抗CLDN18.2人源化抗体。本发明的抗体能够高特异性地结合抗原，具有高亲和力和高生物活性，可特异性结合人CLDN18.2抗原分子，在体外和体内均可高效地抑制肿瘤。
-
公开(公告)号：WO2023081825A2
公开(公告)日：2023-05-11
申请号：PCT/US2022/079304
申请日：2022-11-04
Applicant: UNIVERSITY OF KANSAS
Inventor： MOSKOVITZ, Jackob , SMITH, Adam, S. , GAO, Fei, Philip
Abstract: A hybrid polypeptide can be used to prepare a Met-rich protein includes: a histidine tag region; a solubility promoter region adjacent to the histidine tag region; a methionine-rich region, wherein the solubility promoter region is between the histidine tag and the methionine-rich region; and at least one cleavage site between the solubility promoter region and the methionine-rich region, such that cleavage produces a methionine-rich polypeptide. A method of producing a MetO-rich polypeptide includes: cleaving the Met-rich region from the hybrid polypeptide to produce the Met-rich polypeptide; and oxidizing a plurality of methionine residues in the Met-rich polypeptide to form the MetO-rich polypeptide. A method of immunizing a subject against MetO-containing proteins can use the MetO-rich polypeptides to produce anti-MetO antibodies.
-
公开(公告)号：WO2023081783A1
公开(公告)日：2023-05-11
申请号：PCT/US2022/079253
申请日：2022-11-03
Applicant: THINK BIOSCIENCE, INC. , THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE , O'CONNOR, Nolan , MARKLEY, Andrew , EDSTROM, Hannah
Inventor： FOX, Jerome Michael , FODERARO, Tom , SARKAR, Ankur Kulshreshtha , TRAYLOR, Matthew , KRAMER, Levi Daniel , DONOVAN, Gregory
Abstract: Provided are high-throughput screens for biologically active modulators of a target enzyme that mimic or recreate natural processes of diversification and selection. In some embodiments, the platform comprises one or more expression systems including without limitation (i) a two-hybrid system that, when expressed in a cell, links survival of the cell to the modulation of a therapeutic target, and (ii) a metabolic system that enables the biosynthesis of structurally varied modulators of the therapeutic agent.
-
Patent Agency Ranking
公开(公告)号：WO2023081754A1
公开(公告)日：2023-05-11
申请号：PCT/US2022/079218
申请日：2022-11-03
Applicant: DANA-FARBER CANCER INSTITUTE, INC.
Inventor： LOHR, Jens G. , KNOECHEL, Birgit
Abstract: Disclosed are cluster CAR and therapeutic payload nucleic acids, immune cells containing them, and uses thereof for controllable adoptive cell therapy and killing CAR T-cell resistant tumor cells.
-
7.发明申请
公开(公告)号：WO2023077206A1
公开(公告)日：2023-05-11
申请号：PCT/BR2022/050425
申请日：2022-11-07
Applicant: UNIVERSIDADE FEDERAL DO RIO DE JANEIRO - UFRJ , UNIVERSIDADE FEDERAL DE SERGIPE , LA JOLLA INSTITUTE FOR IMMUNOLOGY
Inventor： ALINE, Aline Silva Barreto , JOAO ANTONIO, João Antônio Barbosa Martins Silva , PRISCILA, Priscila Lima Dos Santos Almeida , TATIANA, Tatiana Leão Dos Santos Dos Reis , PAULA, Paula Mello De Luca , DANIELA, Daniela Santoro Rosa , CRISTIANE, Cristiane Bani Corrêa , ROQUE, Roque Pacheco De Almeida , JOHN, John Sidney , ALESSANDRO, Alessandro Sette , ANGELA, Angela Maria Da Silva , IAM, Iam Palatnik De Sousa , MARIANA, Mariana Nobre Farias De Franca , RAFAEL, Rafael Ciro Marques Cavalcante , CLARISA, Clarisa Beatriz Palatnik De Sousa
IPC: C07K14/44 , C07K19/00 , A61K39/008 , G01N33/53 , A61P33/02
Abstract: Esta invenção consiste em epítopos geneticamente modificados e proteínas multiepítopos compostas por estes epítopos geneticamente modificados para evitar a formação de neoepítopos. A proteína multiAAA está composta por epítopos modificados geneticamente através da adição de três resíduos de Alanina. A proteína multiGPGPG está composta por epítopos modificados geneticamente através da adição de resíduos de Glicina-Prolina-Glicina-Prolina-Glicina. Ambas proteínas são formuladas como composições imunogênicas. Esta invenção visa otimizar a eficácia vacinal e potência imunológica de uma vacina contra a leishmaniose através do uso dos seus epítopos mais potentes, promíscuos e de maior cobertura populacional mundial e ainda resolver o problema da ausência de vacina contra a leishmaniose visceral humana, uma doença letal em expansão no Brasil e no mundo.
-
公开(公告)号：WO2023072103A1
公开(公告)日：2023-05-04
申请号：PCT/CN2022/127476
申请日：2022-10-25
Applicant: 北京卡替医疗技术有限公司
Abstract: 提供了一种能够识别受试者自体抗原的来自供者的同种异体免疫细胞，其中受试者与供者在HLA-A、HLA-B和HLA-C基因座中分别存在至少一个相同的等位基因。还提供了包含该免疫细胞的药物组合物，以及该免疫细胞的制备方法和用途。
-
公开(公告)号：WO2023068328A1
公开(公告)日：2023-04-27
申请号：PCT/JP2022/039089
申请日：2022-10-20
Applicant: 国立大学法人東京大学
IPC: C12N15/11 , A61K31/7088 , A61K38/02 , A61K38/17 , A61K39/395 , A61K45/00 , A61K47/56 , A61K47/62 , A61K47/68 , A61K48/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61P35/00 , C07K14/47 , C07K19/00 , C12N15/115 , C12N15/12 , C12N15/62 , C12N15/63
Abstract: ユビキチン化の困難な標的ペプチドであってもユビキチン－プロテアソーム系に誘導し、分解することのできる新規ユビキチン創薬技術を開発し、提供することである。標的ペプチドに結合する結合因子を一又は連結した二以上のユビキチンのC末端に連結した標的ペプチド分解誘導剤を提供する。
-
公开(公告)号：WO2023066133A1
公开(公告)日：2023-04-27
申请号：PCT/CN2022/125135
申请日：2022-10-13
Applicant: 普米斯生物技术（珠海）有限公司
IPC: C07K16/30 , C12N15/11 , C12N15/63 , C12N5/07 , C07K19/00 , A61K39/395 , A61P35/00 , G01N33/577
Abstract: 本发明涉及特异性结合MSLN的纳米抗体或其抗原结合片段，含有所述纳米抗体或其抗原结合片段的组合物，编码所述抗体或其抗原结合片段的核酸及包含其的宿主细胞，以及相关用途。此外，此发明涉及这些抗体或其抗原结合片段的治疗和诊断用途。
-
-
-
-
-
-
-
-
-
Search Results
7734
records
(took 0.043 seconds)
